10-Hour Eating Window Boosts Weight Loss in Obesity

Denmark's Novo Nordisk ⁠said on Thursday its blockbuster ⁠weight-loss drug Wegovy had ⁠been approved ‌in China as the first GLP-1 RA class of drugs for the ‌treatment of MASH.

Obesity is increasing faster among young adults worldwide, even as older adults still carry the greater overall burden, a new analysis of 196 countries over three decades finds.

About 1 in 8 Danish care home residents with T2D admitted from 2018 to 2023 used glucose-lowering drugs, and most continued treatment despite having A1c levels below recommended targets.

With nearly half of patients discontinuing semaglutide within 12 months — especially younger adults — clinicians face a growing challenge in sustaining long-term treatment.

An observational study finds a higher number of symptoms and greater severity among midlife women with type 2 diabetes than among those without.

Novo Nordisk’s phase 3b trial shows once-weekly IcoSema improves glycemic control and weight with less hypoglycemia than insulin glargine U100 in adults with type 2 diabetes.